| Back |
|
Oncology Molecular Imaging, LLC ("OMI"), founded in 2005, focuses on Positron Emission Tomography. Transition Capital Partners has co-developed and invested in this dynamic healthcare service concept with a former CEO of a portfolio company and OMI's management team. Paul Yeoham, a Transition Capital Partners Partner notes "Transition Capital Partners traditionally does not fund start ups, however it does develop long-term relationships with its business owners and viewed this investment as an excellent working partnership in an exciting growth area."
|
| |
